Sugi Predict

Sugi Predict / Compounds / SCHEMBL4669505

SCHEMBL4669505

SCHEMBL4669505

[CH2]c1cc(OC)c(OC)c(C)c1C

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ACHE P22303 1/20 0.50
▸ CYP3A4 P08684 1/20 0.43
▸ MAPT P10636 1/20 0.43
▸ CA9 Q16790 1/20 0.43
▸ PTGS2 P35354 1/20 0.40
▸ TUBB1 Q9H4B7 2/20 0.37
▸ TUBB4A P04350 1/20 0.37
▸ TUBB P07437 1/20 0.37
▸ TUBA3C P0DPH7 1/20 0.37
▸ TUBA1B P68363 1/20 0.37
▸ TUBA4A P68366 1/20 0.37
▸ TUBB4B P68371 1/20 0.37
▸ TUBB3 Q13509 1/20 0.37
▸ TUBB2A Q13885 1/20 0.37
▸ TUBB8 Q3ZCM7 1/20 0.37
▸ TUBA3E Q6PEY2 1/20 0.37
▸ TUBA1A Q71U36 1/20 0.37
▸ TUBA1C Q9BQE3 1/20 0.37
▸ TUBB6 Q9BUF5 1/20 0.37
▸ TUBB2B Q9BVA1 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL684130 0.80 ACHE (0.59) ACHECYP3A4MAPTCA9PTGS2
SCHEMBL3356035 0.78 ACHE (0.62) ACHECYP3A4MAPTCA9PTGS2
SCHEMBL14458264 0.76 ACHE (0.54) ACHECYP3A4MAPTCA9PTGS2
SCHEMBL11859921 0.76 ACHE (0.48) ACHECYP3A4MAPTCA9PTGS2
SCHEMBL12587049 0.73 CYP3A4 (0.54) ACHECYP3A4MAPTCA9TUBB1
SCHEMBL2293349 0.73 ACHE (0.50) ACHECYP3A4MAPTCA9PTGS2
SCHEMBL2118323 0.73 KDM4E (0.42) ACHEMAPTKDM4EALDH1A1HPGD
SCHEMBL7139663 0.73 ACHE (0.50) ACHECYP3A4MAPTCA9PTGS2
SCHEMBL27631190 0.73 ACHE (0.50) ACHECYP3A4MAPTCA9PTGS2
SCHEMBL10717601 0.72 CYP3A4 (0.41) ACHECYP3A4MAPTCA9PTGS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1975246-A1 Label free sequencing on a solid surface using a field effect transistor Micronas Holding GmbH (DE) 2008-10-01 — — EP disclosed
US-7301041-B2 Bi-functional metallocenes, preparation process and use in the labeling or biological molecules BIO MERIEUX (FR) 2007-11-27 — — US disclosed
US-20050038234-A1 Such as 1-[3-O-dimethoxytritylpropyl]-1'-[3'-O-(2-cyanoethyl-N,N-diisopropylphosphoramidityl)propyl]ferrocene for solid phase synthesis of oligonucleotides/peptides BIO MERIEUX 2005-02-17 — — US disclosed
EP-1180111-A4 METHOD AND APPARATUS FOR COMPOUND LIBRARY PREPARATION USING OPTICAL MODULATOR MACROGEN INC (KR) 2003-03-26 — — EP disclosed
US-20020055185-A1 COMPLEX CHEMICAL COMPOUND, SYNTHESIS AND VARIOUS APPLICATIONS OF SAID COMPOUND BIO MERIEUX (FR) 2002-05-09 — — US disclosed
EP-1180111-A1 METHOD AND APPARATUS FOR COMPOUND LIBRARY PREPARATION USING OPTICAL MODULATOR Macrogen Inc. (KR) 2002-02-20 — — EP disclosed
WO-2000047598-A1 METHOD AND APPARATUS FOR COMPOUND LIBRARY PREPARATION USING OPTICAL MODULATOR MACROGEN INC. (KR) 2000-08-17 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050038234-A1 Such as 1-[3-O-dimethoxytritylpropyl]-1'-[3'-O-(2-cyanoethyl-N,N-diisopropylphosphoramidityl)propyl]ferrocene for solid phase synthesis of oligonucleotides/peptides FTH1, DOHH, NSUN2 ACHE 4855/4885CYP3A4 4605/4885MAPT 4249/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.